3-(氨氧基)-N,N-二甲基丙-1-胺二盐酸盐 | 56425-32-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-(氨氧基)-N,N-二甲基丙-1-胺二盐酸盐
• 英文名称: 3-(Aminooxy)-N,N-dimethylpropan-1-amine dihydrochloride
• 英文别名: O-[3-(dimethylamino)propyl]hydroxylamine;dihydrochloride
• CAS: 56425-32-2
• 化学式: C5H16Cl2N2O
• 分子量: 191.1
• InChiKey: ICEFYPRSPSDJFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  环十二酮 、 3-(氨氧基)-N,N-二甲基丙-1-胺二盐酸盐 、 fumarate 生成 1-(Dimethylamino-propoxyimino)cyclododecane
  参考文献：
  名称：

  Cyclododecanone oximes

  摘要：

  本发明涉及新型环十二烷衍生物，其一般式为##STR1##其中R.sup.1和R.sup.2独立地表示氢原子、C.sub.1-6烷基或C.sub.3-8环烷基，或者R.sup.1和R.sup.2与它们所连接的氮原子一起形成含有4到7个碳原子和可选的进一步杂原子（选自氧、硫和氮的群）的杂环，该环可以被C.sub.1-3烷基或苄基取代；A表示C.sub.2-6直链或支链烷基链，以及其光学异构体、酸加成盐和季铵衍生物。本发明还涉及一种类似的制备上述化合物的方法，以及含有该化合物作为活性成分的制药组合物的制备方法。本发明的环十二烷衍生物具有有价值的生物学性质。

  公开号：

  US04285942A1

文献信息

• SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS
  申请人：Baumann Andrew Christian

  公开号：US20060281700A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R 3 , B, Z, Q, p, q and R 1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制细胞或受试者中FLT3酪氨酸激酶活性或表达或减少FLT3激酶活性或表达的方法，包括给予一种法尼基转移酶抑制剂和一种从氨基嘧啶化合物I′的公式中选择的FLT3激酶抑制剂：其中R3、B、Z、Q、p、q和R1如本文所定义。本发明包括治疗和预防方法，用于治疗患有细胞增殖障碍或与FLT3相关的障碍的受试者。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20060281764A1

  公开（公告）日：2006-12-14

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, Q, p, q and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、Q、p、q和R1如本文中所定义，该类化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，该类化合物的用途是在细胞或主体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并且该类化合物的用途是用于预防或治疗主体中的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明进一步涉及包括本发明化合物的药物组合物以及用于治疗癌症和其他细胞增殖紊乱等疾病的方法。
• Indole derivatives, method for preparating same and pharmaceutical compositions containing same
  申请人：Barth Francis

  公开号：US20060089345A1

  公开（公告）日：2006-04-27

  The present invention provides compounds of formula: and also provides their preparation and the pharmaceutical compositions comprising them. These compounds are ligands of CB 2 cannabinoid receptors.

  本发明提供了以下化合物的化学式，并提供了它们的制备方法以及包含它们的药物组合物。这些化合物是CB2大麻素受体的配体。
• Piperazine oxime dervatives having nk-1 receptor antagonistic activity
  申请人：——

  公开号：US20040176389A1

  公开（公告）日：2004-09-09

  The present invention relates to a group of novel piperazine oxime derivatives having interesting NK-1 antagonistic activity. The invention relates to compounds of the general formula (1) wherein: X represents phenyl or pyridyl substituted with 1 or 2 substituents from the group CH 3 , CF 3 , OCH 3 , halogen, cyano and 5-CF 3 -tetrazol-1-yl; Y represents 2- or 3-indolyl, phenyl, 7-aza-indol-3-yl or 3-indazolyl, 2-naphthyl, 3-benzo[b]thiophenyl, 2-benzofuranyl, which groups may be substituted with one or more halogen or alkyl (1-3C); n has the value 0-3; m has the value 0-2; R 1 represents NH 2 , NH-alkyl (1-3C), dialkyl (1-3C)N, morpholino or morpholino substituted with one or two methyl and/or methoxymethyl groups, thiomorpholino, 1,1-dioxothiomorpholino, 2-, 3- or 4-pyridyl or 4-CH 3 -piperazinyl; R 2 is hydrogen, alkyl (1-4C) or phenyl, or R 2 together with (CH 2 ) m wherein m is 1, and the intermediate carbon nitrogen and oxygen atoms forms an isoxazolyl or a 4,5-dihydroisoxazolyl group; R 3 and R 4 independently represent hydrogen or methyl, or R 3 and R 4 together are oxygen. The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions comprising compounds with formula (1) as an active ingredient and the use of these compounds for the treatment of disorders in which neurokinin-1 receptors are involved. 1

  本发明涉及一组新型哌嗪肟衍生物，具有有趣的NK-1拮抗活性。该发明涉及一般式（1）的化合物，其中：X代表苯基或吡啶基，被1或2个取代基取代，所述取代基来自CH3、CF3、O 、卤素、氰基和5- -四唑-1-基；Y代表2-或3-吲哚基、苯基、7-氮杂吲哚-3-基或3-吲唑基、2-萘基、3-苯并[b]噻吩基、2-苯并呋喃基，这些基团可以被一个或多个卤素或烷基（1-3C）取代；n的值为0-3；m的值为0-2；R1代表NH2、NH-烷基（1-3C）、二烷基（1-3C）N、吗啉基或被一个或两个甲基和/或甲氧基甲基取代的吗啉基、硫代吗啉基、1,1-二氧硫代吗啉基、2-、3-或4-吡啶基或4- -哌嗪基；R2是氢、烷基（1-4C）或苯基，或R2与(CH2)m（其中m为1）一起，中间的碳氮和氧原子形成异噁唑基或4,5-二氢异噁唑基；R3和R4独立地代表氢或甲基，或R3和R4一起代表氧。该发明还涉及一种制备新化合物的方法，以及包含式（1）化合物作为活性成分的药物组合物和这些化合物用于治疗涉及神经激肽-1受体的疾病的用途。
• New 17-hydroxyiminomethyl-5beta, 14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0583579A2

  公开（公告）日：1994-02-23

  17-Hydroxyiminomethyl-14β-hydroxy-5β-androstane derivatives of general formula I wherein the symbol , the symbol , R1, R2, R3 and Y have the meaning as indicated in the specification as well as their stereoisomers, Z and E isomers, tautomers, optical isomers and mixtures thereof and their pharmaceutically acceptable salts. Processes for their preparation, pharmaceutical compositions and uses for the making of a medicament containing them are also disclosed.

  通式 I 的 17-羟基亚氨基甲基-14β-羟基-5β-雄甾烷衍生物 其中符号 、符号 、R1、R2、R3 和 Y 以及它们的立体异构体、Z 和 E 异构体、同分异构体、光学异构体和它们的混合物及其药学上可接受的盐的含义如说明书所示。此外，还公开了它们的制备工艺、药物组合物以及制造含有它们的药物的用途。